ZYUS Life Sciences Corporation (ZLSCF)

Market Cap	38.18M -27.5%
Revenue (ttm)	333.84K +2.9%
Net Income	-24.23M
EPS	-0.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,000
Average Volume	4,258
Open	0.0401
Previous Close	n/a
Day's Range	0.0401 - 0.0501
52-Week Range	n/a
Beta	0.78
RSI	34.18
Earnings Date	Apr 30, 2026

About ZYUS Life Sciences

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZLSCF

Financial Performance

In 2024, ZYUS Life Sciences's revenue was 481,000, an increase of 37.04% compared to the previous year's 351,000. Losses were -33.81 million, -20.63% less than in 2023.

Financial numbers in CAD